Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

Could a new drug improve heart and eye health?

BioAge is set to present promising early results for a new drug, BGE-102, during a webcast on May 8, 2026. This oral medication targets the NLRP3 inflammasome, which plays a role in inflammation linked to cardiovascular disease and eye conditions like diabetic macular edema. The presentation will feature insights from leading experts in the field, including professors from prestigious institutions, and will include a live Q&A session for attendees.

This research is particularly relevant for people concerned about heart health and vision as they age. If successful, BGE-102 could help reduce inflammation in the body, which is a key factor in many chronic diseases. The early Phase 1 clinical data indicates that the drug is well-tolerated and has shown reductions in inflammatory markers, suggesting it may offer benefits for those at risk of atherosclerosis or retinal diseases.

Currently, the evidence is in the early stages, with Phase 1 data showing promise but not yet confirming the drug’s effectiveness in larger populations. BioAge plans to release more data in the second half of 2026 and into 2027, which will help clarify the drug’s potential impact on cardiovascular health and diabetic eye diseases. For now, those interested in the latest developments in longevity and health can tune into the webcast for more information and expert insights.

Source: longevity.technology